Last Updated : October 27, 2021
Details
FilesGeneric Name:
anakinra
Project Status:
Withdrawn
Therapeutic Area:
Still's disease
Manufacturer:
Swedish Orphan Biovitrum AB
Call for patient/clinician input open:
Brand Name:
Kineret
Project Line:
Reimbursement Review
Project Number:
SR0662-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient/clinician input open | November 16, 2020 |
| Call for patient/clinician input closed | January 15, 2021 |
| Clarification:
- Patient input submission received from Arthritis Consumer Experts and Canadian Arthritis Patient Alliance / Arthritis Society/ Cassie and Friends |
|
| Submission received | December 21, 2020 |
| Submission accepted | January 12, 2021 |
| Review initiated | January 13, 2021 |
| Clarification:
- Submission temporarily suspended - Voluntarily withdrawn by the sponsor on 27 Oct 2021
|
|
Files
Last Updated : October 27, 2021